Assembly Biosciences, Inc. (ASMB)

$2.13

+0.02 (+0.95%)
Rating:
Recommendation:
Buy
Symbol ASMB
Price $2.13
Beta 0.691
Volume Avg. 0.48M
Market Cap 103.171M
Shares () -
52 Week Range 1.32-3.94
1y Target Est -
DCF Unlevered ASMB DCF ->
DCF Levered ASMB LDCF ->
ROE -65.14% Strong Sell
ROA -77.27% Strong Sell
Operating Margin -
Debt / Equity 10.86% Neutral
P/E -
P/B 0.70 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ASMB news


Dr. John McHutchison
Healthcare
Biotechnology
NASDAQ Global Select

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and Arbutus Biopharma Corporation; and Antios Therapeutics, Inc. to evaluate a triple combination treatment in patients with chronic hepatitis B virus infection. It also has strategic license agreements with Indiana University Research and Technology Corporation; and Door Pharmaceuticals, LLC. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.